Given these promising hints of potential biomarkers, the importance of understanding the biology surrounding the tumor microenvironment, the modulation of NK cells, and the role that both effector or exhausted CD8+ T cells and TILs play in responders versus non-responders to ICB therapy is imperative to develop clinically informative predictive biomarkers of response (Figure 1). Here, CD8A is linked to neoplasm.